secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0001193125-22-204195
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm EVP Chief Development Officer Ran Frenkel to depart Aug 15; Stuart Poulton promoted to succeed
--------------------------------------------------------------------------------

- Ran Frenkel to cease as EVP, Chief Development Officer effective August 15, 2022.
- Stuart Poulton promoted to EVP, Chief Development Officer effective July 27, 2022.
- Poulton previously SVP, Strategy and Portfolio Management since Feb 2022; 25+ years at AbbVie, Amgen, Eli Lilly.
- Data sciences, clinical pharmacology, data management, medical writing, quality consolidated under Poulton or CMO Reshma Rangwala.
- Company plans separation and consulting agreements with Frenkel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312522204195/0001193125-22-204195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312522204195/d324083d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-204195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer